Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Expected to Post Earnings of $0.10 Per Share

Equities analysts forecast that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will announce earnings of $0.10 per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Arrowhead Pharmaceuticals’ earnings. The highest EPS estimate is $0.19 and the lowest is $0.06. Arrowhead Pharmaceuticals posted earnings of ($0.12) per share in the same quarter last year, which would indicate a positive year over year growth rate of 183.3%. The business is scheduled to report its next quarterly earnings results on Tuesday, December 10th.

According to Zacks, analysts expect that Arrowhead Pharmaceuticals will report full year earnings of $0.73 per share for the current year, with EPS estimates ranging from $0.60 to $0.89. For the next year, analysts expect that the business will report earnings of ($0.25) per share, with EPS estimates ranging from ($0.83) to $0.05. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Monday, August 5th. The biotechnology company reported $0.21 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.34 by ($0.13). The firm had revenue of $42.70 million during the quarter, compared to analysts’ expectations of $59.05 million. Arrowhead Pharmaceuticals had a net margin of 33.28% and a return on equity of 26.27%.



ARWR has been the subject of several research analyst reports. ValuEngine downgraded shares of Arrowhead Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 1st. TheStreet upgraded shares of Arrowhead Pharmaceuticals from a “d” rating to a “c+” rating in a research report on Thursday, May 30th. BidaskClub downgraded shares of Arrowhead Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. B. Riley upped their price target on shares of Arrowhead Pharmaceuticals from $32.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, August 19th. Finally, Piper Jaffray Companies upped their price target on shares of Arrowhead Pharmaceuticals from $33.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Arrowhead Pharmaceuticals has an average rating of “Buy” and an average price target of $33.70.

Shares of NASDAQ:ARWR traded down $0.75 during mid-day trading on Friday, hitting $30.14. The stock had a trading volume of 1,230,102 shares, compared to its average volume of 1,723,987. The company has a market cap of $2.93 billion, a PE ratio of -46.37 and a beta of 1.51. Arrowhead Pharmaceuticals has a 12-month low of $10.41 and a 12-month high of $36.80. The company’s 50 day moving average is $30.88 and its 200-day moving average is $24.26.

In other Arrowhead Pharmaceuticals news, Director Michael S. Perry sold 85,000 shares of the stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $30.00, for a total value of $2,550,000.00. Following the completion of the sale, the director now owns 121,000 shares in the company, valued at approximately $3,630,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Michael S. Perry sold 100,000 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $28.90, for a total transaction of $2,890,000.00. Following the completion of the sale, the director now owns 121,000 shares of the company’s stock, valued at approximately $3,496,900. The disclosure for this sale can be found here. In the last quarter, insiders sold 202,756 shares of company stock valued at $5,930,243. Insiders own 4.80% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in ARWR. Sound Income Strategies LLC purchased a new stake in Arrowhead Pharmaceuticals in the 2nd quarter worth approximately $34,000. Acadian Asset Management LLC bought a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at $34,000. Mascoma Wealth Management LLC bought a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at $46,000. Pearl River Capital LLC bought a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at $111,000. Finally, TCI Wealth Advisors Inc. raised its holdings in shares of Arrowhead Pharmaceuticals by 1,609.0% during the 2nd quarter. TCI Wealth Advisors Inc. now owns 5,298 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 4,988 shares in the last quarter. Institutional investors own 80.11% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.

Featured Story: How much can an individual set aside as a catch-up contribution?

Get a free copy of the Zacks research report on Arrowhead Pharmaceuticals (ARWR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.